Sunday - December 7, 2025
Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences
November 04, 2025
NEW YORK, Nov. 4 [Category: BizFinancial Services] -- Blackstone, an investment firm, posted the following news release:

* * *

Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences

*

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam's AMVUTTRA from funds managed by Blackstone Life Sciences ("Blackstone") for $310 millio . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products